Schedule 13G ownership disclosure

Keros Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 492327101

Event date: 2025-10-20

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • D. E. Shaw & Co., L.P.

    Shares: 1,545,948.00 · Class: 5.1%

  • D. E. Shaw & Co., L.L.C.

    Shares: 1,537,348.00 · Class: 5.0%

  • David E. Shaw

    Shares: 1,545,948.00 · Class: 5.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-102591
Form type
SCHEDULE 13G
Filer
D. E. SHAW & CO, L.P.
CIK
CIK 1009268
Filed
Oct 27, 2025
Reporting period
Oct 20, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub